NEUROCRINE BIOSCIENCES INC (NBIX)       108.22  -2 (-1.81%)

108.22  -2 (-1.81%)

US64125C1099 - Common Stock

NEUROCRINE BIOSCIENCES INC108.22

NASDAQ:NBIX (2/2/2023, 9:01:59 AM)-2 (-1.81%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology

Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend

Overview
Earnings (Last) 11-01 2022-11-01/bmo Earnings (Next) 02-09 2023-02-09
Ins Owners 1.04% Inst Owners 93.3%
Market Cap 10.40B Shares 96.13M
PE 189.86 Fwd PE 28.81
Dividend Yield N/A Analysts 77.65
IPO 05-23 1996-05-23

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

NBIX Daily chart

Company Profile

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 900 full-time employees. The firm is focused on discovering, developing and marketing of pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis and uterine fibroids. Its product pipeline includes INGREZZA (valbenazine), which provides a once-daily dosing treatment option for tardive dyskinesia and has three dosing options (40 milligram (mg), 60 mg and 80 mg capsules); ONGENTYS (opicapone) is an adjunctive therapy to levodopa/carbidopa in patients with Parkinson’s disease; ORILISSA (elagolix) is used for the management of moderate to severe endometriosis pain in women, and ORIAHNN (elagolix, estradiol, and norethindrone acetate and elagolix capsules) is a non-surgical, oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in women.

Company Info

NEUROCRINE BIOSCIENCES INC

12780 El Camino Real

San Diego CALIFORNIA 92130

P: 18586177600.0

CEO: Kevin C. Gorman

Employees: 900

Website: https://www.neurocrine.com/

NBIX News

News Image8 days ago - MarketBeatPliant Therapeutics Gaps 34% Higher: More Upside To Come?

Pliant Therapeutics zoomed 34% higher and added to that gain in the next session.This followed good news about clinical trials for a lung-condition treatment.

News Image9 days ago - InvestorPlace7 A-Rated Stocks to Buy for Less Than $25

These seven stocks to buy for less than $25 per share are strong opportunities in today's resilient yet uncertain market.

News Image13 days ago - The Motley FoolWhy Voyager Therapeutics Stock Is Sinking This Week

Investors are taking profits on this red-hot stock this week.

News Image16 days ago - Neurocrine Biosciences, Inc.Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2022 Financial Results

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2022 financial results...

News Image20 days ago - Investor's Business DailyStock Market Rally Gains Steam As Inflation Cools; Tesla Price Cuts, Big Earnings In Focus: Weekly Review

Sharp Tesla price cuts and some notable earnings were in focus.

News Image24 days ago - InvestorPlaceVoyager Therapeutics (VYGR) Stock Gains 18% on Gene Therapy Deal

Voyager Therapeutics' lucrative arrangement with a fellow biotech business is putting VYGR stock traders in a buying mood today.

NBIX Twits

Here you can normally see the latest stock twits on NBIX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example